Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases
Identification of new markers for BSE in collaboration with Roche Applied Science
ExonHit applied its DATAS® RNA profiling technology on blood samples from bovines provided by Roche Applied Science and has identified early pre-symptomatic disease markers. The resulting RNA splicing markers were validated with 10 individual whole blood samples of BSE-infected cattle and 10 individual whole blood samples of healthy control animals by two technologically different means: micro array analysis at ExonHit and real-time PCR at Roche with the Roche LightCycler Instrument. Both validation setups revealed the same set of three markers that clearly discriminate between BSE-infected and healthy individuals. ExonHit retains all IP rights on the markers identified and diagnostics use.
Most read news
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.